Raghavendra Upadhya
Overview
Explore the profile of Raghavendra Upadhya including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
797
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Attaluri S, Upadhya R, Kodali M, Madhu L, Upadhya D, Shuai B, et al.
Front Immunol
. 2025 Feb;
16:1557065.
PMID: 39958343
[This corrects the article DOI: 10.3389/fimmu.2022.853000.].
2.
Gurjar S, Bhat A R, Upadhya R, Shenoy R
Lipids Health Dis
. 2025 Jan;
24(1):5.
PMID: 39773634
Metabolic dysfunction-associated steatotic liver disease (MASLD) is an asymptomatic, multifaceted condition often associated with various risk factors, including fatigue, obesity, insulin resistance, metabolic syndrome, and sleep apnea. The increasing burden...
3.
Madhu L, Kodali M, Upadhya R, Rao S, Somayaji Y, Attaluri S, et al.
J Extracell Vesicles
. 2024 Nov;
13(11):e12519.
PMID: 39499013
As current treatments for Alzheimer's disease (AD) lack disease-modifying interventions, novel therapies capable of restraining AD progression and maintaining better brain function have great significance. Anti-inflammatory extracellular vesicles (EVs) derived...
4.
Rao S, Madhu L, Babu R, Nagarajan A, Upadhya R, Narvekar E, et al.
bioRxiv
. 2024 Jul;
PMID: 39071270
Background: One of the hallmarks of Alzheimer's disease (AD) is the buildup of amyloid beta-42 (Aβ-42) in the brain, which leads to various adverse effects. Therefore, therapeutic interventions proficient in...
5.
Gopinathan A, Sankhe R, Rathi E, Kodi T, Upadhya R, Pai K, et al.
J Biomol Struct Dyn
. 2024 Apr;
:1-14.
PMID: 38686917
Despite considerable improvement in therapy and diagnosis, brain tumors remain a global public health concern. Among all brain tumors, 80% are due to Glioblastoma. The average survival rate of a...
6.
R A, K S, Chandran D, Hegde S, Upadhya R, Se P, et al.
Stem Cell Res Ther
. 2024 Apr;
15(1):108.
PMID: 38637847
Background: Epilepsy affects ∼60 million people worldwide. Most antiseizure medications in the market act on voltage-gated sodium or calcium channels, indirectly modulating neurotransmitter GABA or glutamate levels or multiple targets....
7.
Madhu L, Kodali M, Upadhya R, Rao S, Shuai B, Somayaji Y, et al.
bioRxiv
. 2024 Jan;
PMID: 38293018
Antiinflammatory extracellular vesicles (EVs) derived from human induced pluripotent stem cell (hiPSC)-derived neural stem cells (NSCs) hold promise as a disease-modifying biologic for Alzheimer's disease (AD). This study directly addressed...
8.
Ayyubova G, Kodali M, Upadhya R, Madhu L, Attaluri S, Somayaji Y, et al.
J Neuroinflammation
. 2023 Dec;
20(1):297.
PMID: 38087314
Extracellular vesicles (EVs) released by human induced pluripotent stem cell-derived neural stem cells (hiPSC-NSCs) are enriched with miRNAs and proteins capable of mediating robust antiinflammatory activity. The lack of tumorigenic...
9.
Alotaibi A, Gadekar V, Gundla P, Mandarthi S, Jayendra N, Tungekar A, et al.
Infect Agent Cancer
. 2023 Aug;
18(1):47.
PMID: 37641095
Background: Esophageal squamous cell carcinoma (ESCC) has a poor prognosis and is one of the deadliest gastrointestinal malignancies. Despite numerous transcriptomics studies to understand its molecular basis, the impact of...
10.
Attaluri S, Jaimes Gonzalez J, Kirmani M, Vogel A, Upadhya R, Kodali M, et al.
Front Aging Neurosci
. 2023 Jul;
15:1200445.
PMID: 37424631
Introduction: Extracellular vesicles (EVs) released by human-induced pluripotent stem cell (hiPSC)-derived neural stem cells (NSCs) have robust antiinflammatory and neurogenic properties due to therapeutic miRNAs and proteins in their cargo....